Get the Stockscreener App
25.95
2.55%
-0.68
After Hours:
25.88
-0.07
-0.27%
Harmony Biosciences Holdings Inc stock is traded at $25.95, with a volume of 921.14K.
It is down -2.55% in the last 24 hours and down -19.63% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$26.63
Open:
$26.59
24h Volume:
921.14K
Relative Volume:
1.20
Market Cap:
$1.49B
Revenue:
$681.88M
Net Income/Loss:
$122.63M
P/E Ratio:
12.30
EPS:
2.11
Net Cash Flow:
$220.18M
1W Performance:
-3.10%
1M Performance:
-19.63%
6M Performance:
-7.12%
1Y Performance:
-25.52%
1-Day Range:
$25.91
$26.97
1-Week Range:
$25.91
$26.97
52-Week Range:
$25.91
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
25.95 | 1.54B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
UBS Maintains HRMY Rating, Lowers Price Target to $43.00 | HRMY Stock News - GuruFocus
What Wall Street predicts for Harmony Biosciences Holdings Inc. stock priceEntry Point & Daily Oversold Bounce Ideas - newser.com
UBS lowers Harmony Biosciences stock price target to $43 on competitive pressure - Investing.com
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $43 at UBS - StreetInsider
Published on: 2025-10-14 23:52:13 - newser.com
Long term hold vs stop loss in Harmony Biosciences Holdings Inc.2025 Geopolitical Influence & Daily Chart Pattern Signals - newser.com
Harmony Biosciences Holdings (HRMY) Stock Analysis: Unveiling a Potential 69% Upside for Investors - DirectorsTalk Interviews
Harmony Biosciences Holdings Inc. stock trend outlook and recovery pathWeekly Trend Recap & Smart Money Movement Tracker - newser.com
Custom watchlist performance reports with Harmony Biosciences Holdings Inc.2025 Market Sentiment & AI Optimized Trade Strategies - newser.com
Published on: 2025-10-13 07:02:21 - newser.com
Harmony Biosciences Hits 52-Week Low at $26.15 Amid Market Turbulence - Markets Mojo
Harmony Biosciences Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Harmony Biosciences (NASDAQ:HRMY) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Harmony Biosciences Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Does Harmony Biosciences Holdings Inc. show high probability of reboundGlobal Markets & Technical Buy Zone Confirmations - newser.com
Can Harmony Biosciences Holdings Inc. hit a new high this monthJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Using AI based signals to follow Harmony Biosciences Holdings Inc.July 2025 News Drivers & Daily Technical Forecast Reports - newser.com
Harmony Biosciences stock hits 52-week low at $26.26 By Investing.com - Investing.com Nigeria
What analysts say about Harmony Biosciences Holdings Inc stockEarnings Volatility Patterns & Amplify Gains With Picks - earlytimes.in
Harmony Biosciences (NASDAQ:HRMY) Hits New 1-Year LowWhat's Next? - MarketBeat
Harmony Biosciences stock hits 52-week low at $26.26 - Investing.com India
Robeco Institutional Asset Management B.V. Takes $1.48 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Sahm
Is Harmony Biosciences (HRMY) the Oversold Biotech Stock to Buy Now? - MSN
Using Bollinger Bands to evaluate Harmony Biosciences Holdings Inc.Weekly Trade Report & Weekly Breakout Watchlists - newser.com
Understanding Harmony Biosciences Holdings Inc.’s price movementOil Prices & Low Drawdown Investment Strategies - newser.com
What drives Harmony Biosciences Holdings Inc stock priceSector Leadership Analysis & Master Stock Selection - earlytimes.in
Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights - MyChesCo
Exit strategy if you’re trapped in Harmony Biosciences Holdings Inc.July 2025 Trends & Stock Portfolio Risk Management - newser.com
Harmony Biosciences Hits New 52-Week Low at $26.26 - Markets Mojo
Harmony Biosciences (HRMY): Assessing Valuation After RECONNECT Trial Disappointment for ZYN002 in Fragile X Syndrome - Yahoo Finance
H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback - MSN
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates - MSN
10 Best Low Priced Growth Stocks to Buy Now - Insider Monkey
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of “Buy” from Analysts - Defense World
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harmony Biosciences Holdings Inc Stock (HRMY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kapadia Sandip | CHIEF FINANCIAL OFFICER |
Aug 15 '25 |
Sale |
36.50 |
21,573 |
787,378 |
0 |
2.96%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):